Skip to content
Bomb Report – Lifestyle
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
March 6, 2026
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 6, 2026
←
Previous Page
1
2